AZD4547

Name: AZD4547
Brand: Selleck Chemicals
SKU: S2801
Rating: 5 (91 reviews)

For research use only.

Catalog No.S2801 Synonyms: ABSK 091

91 publications

CAS No. 1035270-39-3

AZD4547 (ABSK 091) is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Selleck's AZD4547 has been cited by 91 publications

Nature, 2021, 595(7869):730-734

PubMed: 34290403 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Nature, 2018, 553(7686):101-105

PubMed: 29258295 ( click the link to review the publication )

Science, 2017, 10.1126/science.aan4368

PubMed: 29191878 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Acta Neuropathol, 2021, 10.1007/s00401-021-02327-x

PubMed: 34046693 ( click the link to review the publication )

Sci Adv, 2021, 7(7)eabd2645

PubMed: 33579708 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(20)e2100342118

PubMed: 33975953 ( click the link to review the publication )

EMBO Mol Med, 2021, 13(9):e13193

PubMed: 34369083 ( click the link to review the publication )

Cancer Res, 2021, canres.2276.2020

PubMed: 33685992 ( click the link to review the publication )

Cancer Res, 2021, canres.4048.2020

PubMed: 34083250 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):82

PubMed: 34344433 ( click the link to review the publication )

Cells, 2021, 10(6)1318

PubMed: 34070622 ( click the link to review the publication )

FASEB J, 2021, 35(2):e21286

PubMed: 33484478 ( click the link to review the publication )

J Transl Med, 2021, 19(1):401

PubMed: 34551773 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(46):29025-29034

PubMed: 33144503 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

EBioMedicine, 2020, 62:103131

PubMed: 33254023 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00562-0

PubMed: 33119860 ( click the link to review the publication )
Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00567-3

PubMed: 33288861 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

EMBO Mol Med, 2020, e11793

PubMed: 32720440 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2020, 21(1):61

PubMed: 32795383 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):67

PubMed: 32070424 ( click the link to review the publication )

Cancer Immunol Res, 2020, 8(12):1542-1553

PubMed: 33093218 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):372

PubMed: 31438996 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

Mol Cancer Res, 2019,

PubMed: 30257990 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(4):2933-2942

PubMed: 30761743 ( click the link to review the publication )

J Cell Mol Med, 2019, 101111/jcmm14793

PubMed: 31692229 ( click the link to review the publication )

Sci Rep, 2019, 9(1):8726

PubMed: 31217507 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1875

PubMed: 30755670 ( click the link to review the publication )

Sci Rep, 2019, 9(1):6004

PubMed: 30979919 ( click the link to review the publication )

Front Pharmacol, 2019,

PubMed: 31998131 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):432-440

PubMed: 30562682 ( click the link to review the publication )

Reprod Sci, 2019, 26(7):979-987

PubMed: 30270745 ( click the link to review the publication )
Ocul Immunol Inflamm, 2019, 10.1080/09273948.2019.1672196

PubMed: 31657648 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Oncol Lett, 2019, 17(2):2303-2307

PubMed: 30719110 ( click the link to review the publication )

Hepatology, 2018, 10.1002/hep.30127

PubMed: 30067876 ( click the link to review the publication )

Cancer Lett, 2018, 427:38-48

PubMed: 29679612 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(5):850-870

PubMed: 29371290 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12087

PubMed: 30108259 ( click the link to review the publication )

J Biol Chem, 2018, 293(38):14839-14849

PubMed: 30093411 ( click the link to review the publication )

J Proteomics, 2018, 170:130-140

PubMed: 28842319 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Clin Cancer Res, 2017, 15;23(18):5527-5536

PubMed: 28630215 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Oncogene, 2017, 10.1038/onc.2016.512

PubMed: 28263980 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0183181

PubMed: 28806774 ( click the link to review the publication )

J Med Invest, 2017, 64(3.4):262-265

PubMed: 28954993 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(6):10007-10024

PubMed: 28052020 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115596-115608

PubMed: 29383184 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(15):3884-93

PubMed: 26936917 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3285-94

PubMed: 27197170 ( click the link to review the publication )

Int J Cancer, 2016,

PubMed: 26481559 ( click the link to review the publication )
Oncogene, 2016, 10.1038/onc.2016.216

PubMed: 27345413 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(1):9-23

PubMed: 26494904 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

J Biol Chem, 2015, 290(44):26752-64

PubMed: 26370090 ( click the link to review the publication )

Scand J Rheumatol, 2015, 6:1-10

PubMed: 25743336 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0123967

PubMed: 26053020 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124562

PubMed: 25893435 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3237-1

PubMed: 25691251 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25576915 ( click the link to review the publication )

Cell Physiol Biochem, 2014, 33(3):633-45

PubMed: 24642893 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(18):3535-45

PubMed: 25022753 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description

Features

Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.

Targets

FGFR1 ^[1] (Cell-free assay)	FGFR3 ^[1] (Cell-free assay)	FGFR2 ^[1] (Cell-free assay)	KDR ^[1] (Cell-free assay)
0.2 nM	1.8 nM	2.5 nM	24 nM

In vitro

Compared to FGFR1-3, AZD4547 displays weaker activity against FGFR4 with IC50 of 165 nM. AZD4547 only inhibits recombinant VEGFR2 (KDR) kinase activity with IC50 of 24 nM, in the in vitro selectivity test against a diverse panel of representative human kinases. AZD4547 at 0.1 μM exhibits no activity against a range of recombinant kinases including ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2, and PI3-kinase. Consistently, the potent selectivity of AZD4547 for FGFR1-3 over FGFR4, IGFR, and KDR is also observed in cellular phosphorylation assays. AZD4547 has potent in vitro antiproliferative activity only against tumor cell lines expressing deregulated FGFRs such as KG1a, Sum52-PE, and KMS11 with IC50 of 18-281 nM, and is inactive against MCF7 as well as more than 100 additional tumor cell lines. AZD4547 treatment potently inhibits FGFR and MAPK phosphorylation in human tumor cell lines in a dose-dependent manner. AZD4547 also potently inhibits the phosphorylation of FRS2 and PLCγ, downstream markers of FGFR signaling. Notably, AZD4547 affects the AKT phosphorylation in the breast cell lines, MCF7 and Sum52-PE but not in KG1a and KMS11 lines. AZD4547 treatment significantly induces apoptosis in Sum52-PE and KMS11 cells, dramatically increases G1 arrest but not apoptosis in KG1a cells, and has no effect on cell cycle distribution or apoptosis in MCF7 cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SNU449	M2HhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWS3NkBp	M2POcmlEPTB;MD6wPFIh\|ryP	MlLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlAoRjJ4M{WxN\|IxRC:jPh?=
SK-HEP-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWi3NkBp	NFjjOoxKSzVyPUCuNFg1KM7:TR?=	NYXwfIZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N\|UyOzJyPD;hQi=>
SNU475	MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYfENWdlPzJiaB?=	NU\a[JQ6UUN3ME21MlQh\|ryP	NFXVSXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
Hep3B	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn24O\|IhcA>?	M1X5eWlEPTB;Nj60N{DPxE1?	MmjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlAoRjJ4M{WxN\|IxRC:jPh?=
PLC/PRF5	NWPmcHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV;Ee\|E2PzJiaB?=	NULH[WJyUUN3ME22MlU2KM7:TR?=	MnWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlAoRjJ4M{WxN\|IxRC:jPh?=
Hur7	NH3LeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUPYXXdWPzJiaB?=	M{f4WmlEPTB;Nz6yOUDPxE1?	NXTyflUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N\|UyOzJyPD;hQi=>
HepG2	NW[0Slg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4C5V\|czKGh?	NGfkbVVKSzVyPUiuO\|Mh\|ryP	NIfET3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
SNU449	MYTDcI9vd2enbnnjJIF{e2G7	MVWxJOK2VQ>?	M2C0SVI1KGh?	MnfU[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgQ>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ\|NUGzNlA9N2F-
SK-HEP-1	MljuR4xwdm:pZX7pZ{Bie3OjeR?=	Ml\INUDDvU1?	MV6yOEBp	MYTk[YNz\WG\|ZYOgZ49td267IH\vdo1ifGmxbjDzbYdvcW[rY3HueIx6	NXvzTHZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N\|UyOzJyPD;hQi=>
SNU449	NH\UblRHfW6ldHnvckBCe3OjeR?=	NYryNFczOC1{IN88US=>	MWi0PEBp	MWfjZZV{\XNiYTDk[YNz\WG\|ZTDv[kBHWlN{78{MRWtVNCCjbnSgSXJMKHCqb4PwbI9zgWyjdHnvci=>	NY\vbJZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N\|UyOzJyPD;hQi=>
SK-HEP-1	M3TjXmZ2dmO2aX;uJGF{e2G7	MYKwMVIh\|ryP	MYS0PEBp	MlvHZ4F2e2W\|IHGg[IVkemWjc3Wgc4YhTlKVMv-8kGFMXCxiYX7kJGVTUyCyaH;zdIhwenmuYYTpc44>	MlnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlAoRjJ4M{WxN\|IxRC:jPh?=
BaF3 FLT3-TEL	MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIDXN4xIUTVyPUSuOkDDuSByLkW3O{DPxE1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
BaF3 RET-TEL	NGXScGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NF7Nem1IUTVyPUCuN\|khyrFiMD6wOFgh\|ryP	Mnz5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O\|QyRC:jPh?=
BaF3 Parental	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVLWbll4T0l3MP-5qVExKM7:TR?=	M2fyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mkm0O\|QyLz5{NkK5OFc1OTxxYU6=
MOLM14 FLT3/ITD	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1qwOmdKPTB;MD60PFQhyrFiMD6xOVch\|ryP	NWXYUJQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
MV4-11 FLT3/ITD	NH\5ZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1TibWdKPTB;MD60OVkhyrFiMD6wOFYh\|ryP	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
TT RET C634W	NFTXV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{TP[WdKPTB;Mj65JOKyKDBwOUC0JO69VQ>?	NVXGcWU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
AN3-CA FGFR2 N550K, K310R	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mlu0S2k2OD1yLkCzNUDDuSByLkCyN{DPxE1?	M1;zXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mkm0O\|QyLz5{NkK5OFc1OTxxYU6=
MFE296 FGFR2 N550K	M3ex[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGnaO5ZIUTVyPUCuO\|MxKMLzIECuNFU4KM7:TR?=	MoftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O\|QyRC:jPh?=
MFE280 FGFR2 S252W	NW\Fd3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHTXdHVIUTVyPUCuNlE5KMLzIECuNFc{KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
Ishikawa FGFF2 over exp.	NHy4Wm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXXVOIY1T0l3ME20MlUhyrFiMT61NUDPxE1?	NIXxZXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK5OFc1OSd-Mk[yPVQ4PDF:L3G+
HEC1A Normal FGFR2	MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX\HTVUx97nnMUCg{txO	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
A549	NEe1TWZE\WyuII\pZYJqdGm2eTDBd5NigQ>?	MXOwMlEwOSEQvF2=	NVTMNnd[PDhiaB?=	MVLlcohidmOnczDFdoxwfGmwaXKgbY5lfWOnZDD2bYFjcWyrdImgcI9{ew>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3M{CyNEc,OjZyNUOwNlA9N2F-
SGC-7901	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzYNUBvVS1zMDFOwG0>	MmXDO\|IhcA>?	M{fvfWlEPTBib3[gOU0yOCEQvF2sJIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NUXBU\|NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O\|Y6OTVpPkK1OVc3QTF3PD;hQi=>
HGC-27	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVixJI5ONTFyIN88US=>	M{KyZ\|czKGh?	NYLlOmtsUUN3MDDv[kA2NTFyIN88UUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NWDTWoJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O\|Y6OTVpPkK1OVc3QTF3PD;hQi=>
MKN-28	NIW0XJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGxJI5ONTFyIN88US=>	NUPVcY41PzJiaB?=	Mlq5TWM2OCCxZjC1MVExKM7:TTygbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NHrIW2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW3OlkyPSd-MkW1O\|Y6OTV:L3G+
NCI-N87	M2PKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3j3cVEhdk1vMUCg{txO	MYe3NkBp	M4HZTWlEPTBib3[gOU0yOCEQvF2sJIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NVv0SpRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O\|Y6OTVpPkK1OVc3QTF3PD;hQi=>
KATOIII	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHflcXQyKG6PLUGwJO69VQ>?	MonUO\|IhcA>?	NIDHdmhKSzVyIH;mJFExNTFyMDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NV\nTolmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O\|Y6OTVpPkK1OVc3QTF3PD;hQi=>
SNU-16	Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;6dVEhdk1vMUCg{txO	MYe3NkBp	NGDGN2tKSzVyIH;mJFExNTFyMDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	M2HHeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2PVE2Lz5{NUW3OlkyPTxxYU6=
4T1	NVHNcm9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXHJR\|UxRTBwNkVCtVAvOTFizszN	NH7Leng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0Nlg6Oyd-MkS2OFI5QTN:L3G+
MDA-MB-468	NV;4U2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFi0Z4dKSzVyPUSuPeKyOC56NTFOwG0>	M2izSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
HCT116	NWDRO4VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVPpTYtHUUN3ME2xOU46yrFzLkiyJO69VQ>?	M3\zeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
SW620	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX7JR\|Ux97zgMkCg{txO	MmXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
MDA-MB-231	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn;5TWM2OO,:nkKwJO69VQ>?	MmXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
CT26	NXGxc4FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF7sfpdKSzVy78{eNlAh\|ryP	M2i3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
SW480	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWTJR\|Ux97zgMkCg{txO	M4XaPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
4T1	M2nPR2Fxd3C2b4Ppd{BCe3OjeR?=	MmfkNU4zPS1{MDFOwG0>	NFrXSYkzPCCq	M{nSfolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	M2DkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
KG1a	NYf6N2RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkTqTWM2OD1yLkCxPEDPxE1?	NETubGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2PVkzQCd-MkKzOlk6Ojh:L3G+
Sum52-PE	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIfWfnNKSzVyPUCuNFQyKM7:TR?=	MmXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|Nkm5NlgoRjJ{M{[5PVI5RC:jPh?=
KMS11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVzLTnl2UUN3ME2wMlI5OSEQvF2=	MkDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|Nkm5NlgoRjJ{M{[5PVI5RC:jPh?=
MCF7	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEDseY5KSzVyPkOwJO69VQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4OUmyPEc,OjJ\|Nkm5Nlg9N2F-
KG1	MmLxSpVv[3Srb36gZZN{[Xl?		MU[3NkBpenN?	MnK0TY5pcWKrdHnvckBw\iCIR1\SNUBqdiCqdX3hckBMTzFiY3XscJMh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUBUWkJxQ1PLMVgh[XO\|YYmsJGlEPTBiPTCwMlAxODJizszNMi=>	NHrGTVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|QzPyd-MkexNVc1Ojd:L3G+
RT112	M4PJfmZ2dmO2aX;uJIF{e2G7		NX3FVIl2PzJiaILz	M3Tjc2lvcGmkaYTpc44hd2ZiRlfGVlMhcW5iaIXtZY4hWlRzMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjByME[g{txONg>?	M2X0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3OFI4Lz5{N{GxO\|QzPzxxYU6=
KG1	MoH1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2TTcVczKGi{cx?=	NELiWJNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvHNUBk\WyuczDlfJBz\XO\|aX7nJGZITlJzIHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvODBzOTFOwG0v	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUmzO{c,Ojl5N{W5N\|c9N2F-
KG1	M3jMemFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXy3NkBpenN?	NF7sWWFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvHNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO\|YYmsJGlEPTBiPTCwMlAxOzNizszNMi=>	NVvtPZRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFczODRpPkK4Olg4OjB2PD;hQi=>
SNU16	MoH3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NULGVoNjPzJiaILz	NFTwO3JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPOWVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFAvODB\|NDFOwG0v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6N{KwOEc,Ojh4OEeyNFQ9N2F-
SNU16	Mn\OSpVv[3Srb36gZZN{[Xl?		NYG5[2hqPzJiaILz	MnX3TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDGS2ZTOiCrbjDoeY1idiCVTmWxOkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRk9ES0tvODDhd5NigSxiSVO1NEA:KDBwMECzOkDPxE1w	NHXzVlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|QzPyd-MkexNVc1Ojd:L3G+
SNU16	NF7rPWlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{L1eVczKGi{cx?=	MmTKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVTmWxOkBk\WyuczDlfJBz\XO\|aX7nJGZITlJ{IHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvODB4MjFOwG0v	MoXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{W5N\|coRjJ7N{e1PVM4RC:jPh?=
KG1	M2D1Z2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWi3NkBpenN?	MlPrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDGS2ZTOS22cnHud4xw[2G2ZXSgbJVu[W5iS1exJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4M21VXCCjc4PhfUwhUUN3MDC9JFAvODB4NDFOwG0v	NWezVWg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezOFg2OzdpPkK3N\|Q5PTN5PD;hQi=>
SNU16	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUO5WFZMPzJiaILz	NUP4cWRSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBHT0[UMj3hcZBtcW[rZXSgbJVu[W5iU17VNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gwVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMUO0JO69VS5?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2OEWzO{c,Ojd\|NEi1N\|c9N2F-
KATO III	NHfZZndHfW6ldHnvckBie3OjeR?=		M4LlVlczKGi{cx?=	MYPJcohq[mm2aX;uJI9nKE[JRmKyJIlvKGi3bXHuJGtCXE9iSVnJJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSClZXzsJINwfW62aX7nJItqfC16IHHzd4F6NCCLQ{WwJF0hOC5yMUSxJO69VS5?	NEHJbmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOFY6Oid-Mki3NVQ3QTJ:L3G+
KG1	NWjBfXNVTnWwY4Tpc44h[XO\|YYm=		M{\rNFczKGi{cx?=	MmXvTY5pcWKrdHnvckBw\iCIR1\SNW9ROiCodYPl[EBHT0[UMTDpckBpfW2jbjDLS\|Eh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwh[2:3boTpcochc2m2LUigZZN{[XluIFnDOVAhRSByLkCxOlEh\|ryPLh?=	NIq1Uno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOFY6Oid-Mki3NVQ3QTJ:L3G+
KATO III	MXTGeY5kfGmxbjDhd5NigQ>?		MVy3NkBpenN?	MXvJcohq[mm2aX;uJI9nKE[JRmKyJIlvKGi3bXHuJGtCXE9iSVnJJINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliU2LCM2NEUy16IHHzd4F6NCCLQ{WwJF0hOC5yMkCyJO69VS5?	NVH5cGI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVc1OjdpPkK3NVE4PDJ5PD;hQi=>
SNU16	MVvGeY5kfGmxbjDhd5NigQ>?		MnrTO\|IhcHK\|	NXyzfVVQUW6qaXLpeIlwdiCxZjDGS2ZTOiCrbjDoeY1idiCVTmWxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliY3XscEBkd3WwdHnu[{BscXRvODDhd5NigSxiSVO1NEA:KDBwMEK1OEDPxE1w	NULh[oJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVQ3QTJpPkK4O\|E1Pjl{PD;hQi=>
UM-UC-14	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGfqbFk4OiCqcoO=	NIC3Z2RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGXNMXVENTF2IHPlcIx{KGW6cILld5NqdmdiRlfGVlMh[W[2ZYKgO\|IhcHK\|LDDJR\|UxKD1iMD6wNlY6KM7:TT6=	NXP3NIZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U6OzdpPkK5O\|c2QTN5PD;hQi=>
RT112	NHvF[5JHfW6ldHnvckBie3OjeR?=		MXe3NkBpenN?	NXr6ZXNbUW6qaXLpeIlwdiCxZjDGS2ZTOyCrbjDoeY1idiCUVEGxNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliY3XscEBkd3WwdHnu[{BscXRvODDhd5NigSxiSVO1NEA:KDBwMEK3JO69VS5?	M3n5SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G0OlkzLz5{OEexOFY6OjxxYU6=
UM-UC-14	MmXYSpVv[3Srb36gZZN{[Xl?		NFvKPVg4OiCqcoO=	NFr5VGRKdmirYnn0bY9vKG:oIF\HSnI{KG23dHHueEBqdiCqdX3hckBWVS2XQz2xOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliY3XscEBkd3WwdHnu[{BscXRvODDhd5NigSxiSVO1NEA:KDBwMEK3NUDPxE1w	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNE[5Nkc,Ojh5MUS2PVI9N2F-
RT112	MnHCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NX\xPJBRPzJiaILz	NFLVfopCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLUNVEzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTCwMlAzQTJizszNMi=>	NYfjUnBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1PVk4PDJpPkK3OVk6PzR{PD;hQi=>
H1581	M1PZe2Z2dmO2aX;uJIF{e2G7		MXe3NkBpenN?	MX\Jcohq[mm2aX;uJI9nKE[JRmKxJIlvKGi3bXHuJGgyPThzIHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEL1PDT{05KGG\|c3H5MEBKSzVyIE2gNE4xOzJ7IN88UU4>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{SyO{c,OjdzMUe0Nlc9N2F-
NCI-H1581	NYnzWlRpSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIXLSpc4OiCqcoO=	NV3UOYs5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF3OEGgZ4VtdHNiZYjwdoV{e2mwZzDGS2ZTOSCjZoTldkA4OiCqcoOsJGlEPTBiPTCwMlA1KM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUmzO{c,Ojl5N{W5N\|c9N2F-
B16F10	M4\yVmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHXYSlE4OiCqcoO=	NGnT[JlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDOT[IMUCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEWxJO69VS5?	NIC2XHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUezOlk6Oyd-MkW3N\|Y6QTN:L3G+
A549	Ml;4R5l1d3SxeHnjbZR6KGG\|c3H5		M2jFblczKGi{cx?=	MnvyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xPjJizszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd\|Nkm5N{c,OjV5M{[5PVM9N2F-
NCI-H1581	NEPs[pNHfW6ldHnvckBie3OjeR?=		NHXaPJI4OiCqcoO=	Ml\2TY5pcWKrdHnvckBw\iCIR1\SNUBqdiCqdX3hckBPS0lvSEG1PFEh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwh[2:3boTpcochc2m2LUigZZN{[XluIFnDOVAhRSByLkC2NlYh\|ryPLh?=	M1jLNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G0OlkzLz5{OEexOFY6OjxxYU6=
RT112	NXHHdnVGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M{iwSFczKGi{cx?=	M1XJcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmSxNVIh[2WubIOg[ZhxemW\|c3nu[{BHT0[UMzDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjB6M{ig{txONg>?	MmP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{W5N\|coRjJ7N{e1PVM4RC:jPh?=
RT112	NF75W4xCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2j3dlczKGi{cx?=	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\HSnI{NWGvcHzp[olm\CCqdX3hckBTXDFzMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONOD;NWHQh[XO\|YYmsJGlEPTBiPTCwMlA5QDRizszNMi=>	MkjiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEi1N\|coRjJ5M{S4OVM4RC:jPh?=
NCI-H1581	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEm0SIo4OiCqcoO=	M1XoUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmdHWjFvYX3wcIlncWWmIHj1cYFvKE6FST3INVU5OSClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMQC:PVGSgZZN{[XluIFnDOVAhRSByLkC5NlEh\|ryPLh?=	MlPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEi1N\|coRjJ5M{S4OVM4RC:jPh?=
HeLa 229	NIjib4pEgXSxdH;4bYNqfHliYYPzZZk>		NVTaRlVuPzJiaILz	M3XrOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiMkK5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkG0JO69VS5?	MlXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{[5PVMoRjJ3N{O2PVk{RC:jPh?=
BAF3	NEjsRlZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUPGbmhRPzJiaILz	NVPDdFQ3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXkWJRmKyJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMkKyJO69VS5?	M1HMflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1PVM4Lz5{OUe3OVk{PzxxYU6=
SGC7901	NGjMZ25CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVm3NkBpenN?	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOJQ{e5NFEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuPEDPxE1w	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh{OUWxPUc,Ojd6Mkm1NVk9N2F-
MGC803	M4LZd2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		Ml\sO\|IhcHK\|	MonNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPR1O4NFMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IE[uNkDPxE1w	M{\xW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEK5OVE6Lz5{N{iyPVUyQTxxYU6=
BGC823	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUPYW3d1PzJiaILz	M3S0[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQlfDPFI{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC3Mlkh\|ryPLh?=	NV\1SJVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4Nlk2OTlpPkK3PFI6PTF7PD;hQi=>
HL7702	NVnZZYt3S3m2b4TvfIlkcXS7IHHzd4F6		NETufHI4OiCqcoO=	NFHPOJJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDd5MEKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF6LkKxJO69VS5?	NHXCOVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUezOlk6Oyd-MkW3N\|Y6QTN:L3G+
U-2 OS	MVTxTHRUKHO\|YYm=			MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	NGfaTVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NHniOndyUFSVIIPzZZk>			Mmj3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	M{PRfJFJXFNic4PhfS=>			MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NGm2ZpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MnXKdWhVWyC\|c3H5			NHzBeotyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	Mnv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NHrrUJdyUFSVIIPzZZk>			MomzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NIPSRmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	Mm\xdWhVWyC\|c3H5			M2i1T5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M3j3fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MY\xTHRUKHO\|YYm=			M{\KWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	NX3I[JllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	MYfxTHRUKHO\|YYm=			M3Pse5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
fibroblast cells	M4\IfpFJXFNic4PhfS=>			NUXyNmJxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IHPvcpRzd2xiSHige4lt\CC2eYDlJIZq[nKxYnzhd5Qh[2WubIO=	M2\hPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	M{HDbJFJXFNic4PhfS=>			M1HzTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NV7ldWJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	MlnrdWhVWyC\|c3H5			MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	Mm\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	Mn30dWhVWyC\|c3H5			MmfRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NYLDfnRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NHnofFVyUFSVIIPzZZk>			NEHjeGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	M33XZZFJXFNic4PhfS=>			MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MnrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	M4LqTJFJXFNic4PhfS=>			NIHaR\|ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	MlPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FGFR / FGFR1 / p-AKT / AKT / p-ERK / ERK; PubMed: 28900173 Sci Rep Western blots (cropped) are shown for the indicated proteins in MDA-MB-361, BT474, and SKBR3 cells treated with AZD4547 (0, 1, 3, or 5 µM) for 72 hours. pFRS2; PubMed: 25576915 Oncotarget AZD4547 inhibits FGFR2 pathway activation in SNU16 and KATOIII cells. Cells were incubated with AZD4547 at the indicated doses. Cell lysates were immunoblotted for phospho-FGFR, phospho-FRS2, phospho- and total AKT, and phospho- and total ERK.	28900173 25576915
Growth inhibition assay	Cell viability; PubMed: 28900173 Sci Rep MDA-MB-361, BT474, and SKBR3 ErbB2-overexpressing breast cancer cells were treated with AZD4547 (0, 0.1, 0.3, 1, 3, or 5 µM) for 5 days. Then the viable fraction of each cell line was determined with an MTS assay. Cell viability; PubMed: 25576915 Oncotarget FGFR2-amplified GC cells are selectively sensitive to AZD4547. In vitro CCK-8 assay across a panel of 6 GC cells demonstrated that SNU16 and KATOIII cells were extremely sensitive to AZD4547 with IC50 values of 5-10 nM. Data (n = 6) are presented as mean ± SD.	28900173 25576915

In vivo

Oral administration of AZD4547 at 3 mg/kg twice daily in mice bearing KMS11 tumors results in significant tumor growth inhibition of 53% when compared with vehicle-treated controls, and AZD4547 at 12.5 mg/kg once daily or 6.25 mg/kg twice daily leads to complete tumor stasis, which is associated with dose proportional pharmacodynamic modulation of phospho-FGFR3 and reduced KMS11 tumor cell proliferation. Moreover, oral administration of AZD4547 at 12.5 mg/kg once daily results in 65% tumor growth inhibition in the FGFR1-fusion KG1a xenograft model. At efficacious dose levels, AZD4547 does not exhibit antiangiogenic effects. AZD4547 has no significant effect on blood pressure and therefore lacks in vivo anti-KDR activity. Consistently, dosing of 6.25 mg/kg orally twice daily AZD4547 is inactive in the cediranib-sensitive xenograft models including Calu-6, HCT-15 and LoVo. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse AZD4547 kinase activity: The ability of AZD4547 to inhibit the human recombinant kinase activities of FGFR1-3 is tested using ATP concentrations at, or just below, the respective K_m.
Cell Research:^[1]	- Collapse Cell lines: KG1a, Sum52-PE, KMS11, and MCF7 Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of AZD4547 for 72 hours. The antiproliferative IC50 values are obtained by MTS proliferation assay. For fluorescence-activated cell sorting (FACS), cells are fixed with 70% ethanol and then incubated with propidium iodide/RNase A labeling solution. Cell cycle profiles are assessed with a FACSCalibur instrument and CellQuest analysis software. For apoptotic analysis, cells and media are gently harvested and centrifuged, followed by washing of cell pellets. Cells are then processed for Annexin V-fluorescein isothiocyanate (FITC) staining and propidium iodide uptake. The proportion of cells staining positive for Annexin V are then assessed with a FACSCalibur instrument and quadrant sorting is done by CellQuest analysis software. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female swiss derived nude (nu/nu) and severe combined immunodeficient mice (SCID) injected s.c. with LoVo, HCT-15, Calu-6, KMS11 or KG1a Dosages: 1.5-50 mg/kg Administration: Oral gavage once daily or twice daily (Only for Reference)

References

[1] Gavine PR, et al. Cancer Res, 2012, 72(8), 2045-2056.

Solubility (25°C)

In vitro	DMSO	92 mg/mL (198.45 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD4547 SDF

Molecular Weight	463.57
Formula	C₂₆H₃₃N₅O₃
CAS No.	1035270-39-3
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	ABSK 091
Smiles	CC1CN(CC(N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02824133	Completed	Drug: AZD4547	Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion\|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion	Assistance Publique - Hôpitaux de Paris	September 2015	Phase 1\|Phase 2
NCT01824901	Completed	Drug: docetaxel\|Drug: AZD4547	Recurrent Non-small Cell Lung Cancer\|Squamous Cell Lung Cancer	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	September 2013	Phase 1\|Phase 2
NCT01795768	Unknown status	Drug: AZD 4547	Gastric Cancer\|Oesophageal Cancer\|Breast Cancer\|Squamous Cell Carcinoma of the Lung	Royal Marsden NHS Foundation Trust\|AstraZeneca	September 2012	Phase 2
NCT01791985	Completed	Drug: AZD4547 / anastrozole or letrozole	Breast Cancer	Imperial College London\|Cancer Research UK\|AstraZeneca	July 2012	Phase 1\|Phase 2
NCT01213160	Completed	Drug: AZD4547	Cancer\|Advanced Solid Malignancies	AstraZeneca	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Selective FGFR Inhibitor

PD173074 : FGFR1-selective, IC50=~25 nM.
FDA-approved FGFR Inhibitor

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
Newest FGFR Inhibitor

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
Classic FGFR Inhibitor

Dovitinib (TKI-258, CHIR-258) : Multitargeted RTK inhibitor for class III (FLT3/c-Kit), class IV (FGFR1/3) and class V (VEGFR1-4) RTKs.

Related FGFR Products

Zoligratinib (Debio-1347) ^New

Zoligratinib (Debio-1347, CH5183284, FF284) is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
BLU9931 ^New

BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
PD173074

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.
Infigratinib (BGJ398)

Infigratinib (BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.
SSR128129E

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
LY2874455

LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Dasatinib (BMS-354825)

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD4547